ArticleNeurology2018
Ovarian aging is associated with gray matter volume and disability in women with MS.
Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Sex- and age-related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trials.European journal of neurology · 2024Trial
- Understanding the Role of Hypothalamic-Pituitary-Gonadal Axis in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Biomedicines · 2026Review
- The Neurology of Menopause.Current neurology and neuroscience reports · 2026Review
- The Burden of Multiple Sclerosis in Japan from 1990 to 2021 and Predictions to 2050 Based on the Global Burden of Disease Study 2021.Neuroepidemiology · 2026Article
- Sex and gender as contributors to brain pathophysiology, clinical course, and therapeutic response in multiple sclerosis.Frontiers in behavioral neuroscience · 2026Review
- Assisted Reproduction Therapy in Patients with Multiple Sclerosis: Narrative Review and Practical Recommendations.Healthcare (Basel, Switzerland) · 2025Review
- Menopause Impact on Multiple Sclerosis Disability Progression.JAMA neurology · 2025Article
- Quantitative proteomic analysis of pathological and physiological ovarian aging: model evaluation, molecular mechanisms, and identification of early biomarkers and therapeutic targets.Journal of ovarian research · 2025Article
- Sex-Related Differences in Lifestyle Factors Affecting Multiple Sclerosis Susceptibility and Disease Progression.Brain sciences · 2025Review
- Advancing multiple sclerosis management in older adults.Nature reviews. Neurology · 2025Article
- Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.Neurology · 2025Observational
- The influence of menopause on multiple sclerosis.European journal of neurology · 2025Article
- Immunometabolic profiling in menopausal women with multiple sclerosis: the role of adipokines and hormone therapy.BMJ neurology open · 2025Article
- Global, regional, and national burden of four major neurological diseases in women from 1990 to 2021.Frontiers in public health · 2025Article
- [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].Revista de neurologia · 2024Article
- Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Priority setting: women's health topics in multiple sclerosis.Frontiers in neurology · 2024Article
- Identification of crucial inflammaging related risk factors in multiple sclerosis.Frontiers in molecular neuroscience · 2024Article
- Imaging phenotypic differences in multiple sclerosis: at the crossroads of aging, sex, race, and ethnicity.Frontiers in global women's health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine if ovarian aging as measured by levels of anti-Müllerian hormone (AMH) is associated with pattern of multiple sclerosis (MS) progression in women.
methodsWomen with MS and healthy controls were included from a longitudinal research cohort with up to 10 years follow-up. Plasma AMH levels were measured by ELISA for baseline and years 3, 5, and 8-10. Mixed effects logistic and linear regression models were employed, with adjustments for age, disease duration, and other covariables as appropriate.
resultsAMH levels were similar (0.98-fold difference, 95% confidence interval [CI] 0.69-1.37,
conclusionAs a marker of ovarian aging, lower AMH levels were associated with greater disability and gray matter loss in women with MS independent of chronological age and disease duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.